The Pharma Summit 2011

09.00

CHAIR'S OPENING REMARKS

Iain Scott, Managing Editor, Business Research, Economist Intelligence Unit 

THE NEW PHARMA:  MODELS FOR FUTURE GROWTH

09.15

OPENING ADDRESS: Is there a future for the research-led pharma company?
One of the leading industry figures gives his thoughts about the future of the big pharma business model.

John Lechleiter, Chairman, President and Chief Executive Officer, Eli Lilly

09.45

KEYNOTE ADDRESS: Pharma’s value proposition  - how the industry must change  
The head of strategy at one of the world's biggest pharma companies will outline his perspectives on current industry challenges with reference to GSK's strategy.

David Redfern, Chief Strategy Officer, GlaxoSmithKline

PANEL: Where’s hot and where’s not: Seeking opportunities in tomorrow’s markets
With markets stagnant in much of the developed world, there has been an unprecedented expansion into emerging markets by many of the key pharma players. This panel will explore the following issues:

Jesper Høiland, Senior Vice-president, International Operations, Novo Nordisk
Ken Jones, Chief Operating Officer, Astellas Pharma Europes
Ponni Subbiah, Vice-president, Global Access, Emerging Markets, Pfizer

11.45

PANEL: Forget command and control – try engagement: Repositioning pharma for a new era
Different stakeholders in the value chain, including healthcare providers, patient groups and governments, will discuss the changing demands on the industry and how they can be reconciled with pharma’s commercial interests. Issues for discussion will include:

• How can pharma re-establish trust with patients, investors and diverse stakeholders?
• What do different players in the healthcare system value, and how can the industry meet their needs?
• How can partnering enable the pharma industry to find new revenue streams?
• How does the pharma business model need to change to capture value in new ways?

Patrick Flochel, Partner, EMEIA Life Sciences Leader, Global Life Sciences Centre, Ernst & Young
Jeremy Taylor, Chief Executive, National Voices
Kemal Malik, Member of the Board of Management and Head of Global Development, Bayer HealthCare AG
Håkan Björklund, Chief Executive, Nycomed

Chaired by Peter Collins, Online Business and Finance Editor, The Economist

PRESENTATION: Moving away from the blockbusters: innovative approaches to orphan diseases
The founder of the medical charity AKU Society, will draw on his extensive experience in researching rare diseases to put forward his ideas on how to reorit the pharma industry to be able to enter this neglected market and build a profitable business model from it.

Nicolas Sireau, Chairman, AKU Society

Chaired by: Tom Standage, Digital Editor, The Economist

PANEL:  The case for personalised medicine – is this the future and, if so, how will we pay for it?
It is becoming clear that targeting particular treatments to smaller patient populations is more effective than a “one-size-fits-all” approach. But is there an upside for drug manufacturers? Are there benefits which will outweigh the potential increase in marketing and R&D costs? This panel will look at new developments in personalised medicine and discuss whether it can be made to pay its way.

David Bott, Director of Innovation, Technology Strategy Board
Martin Mackay, President, R&D, AstraZeneca
Debasish Roychowdhury, Senior Vice-president and Chief Oncology Officer, Sanofi-Aventis
Felix Frueh, Vice-president, Research and Development, Personalized Medicine, Medco Health Solutions

Chaired by: Tom Standage, Digital Editor, The Economist

DRINKS RECEPTION: SPONSORED BY ENTERPRISE IRELAND

To be held at the Irish Embassy (transportation will be provided)

Felix Frueh, President, Medco Health Institute

With a background in academia and at the FDA, Felix has a wealth of valuable experience to bring to the debate, and delegates will also benefit from his in-depth knowledge of the US healthcare landscape.

Håkan Björklund, Chief Executive Officer, Nycomed

As leader of a growing pharma company which is now in the world’s top 25, Håkan can offer a welcome insight into which strategies will pay off for the industry to position itself in a rapidly changing healthcare landscape.

Kemal Malik, Member of the Board of Management and Head of Global Development, Bayer HealthCare 

With a background in medicine as well as a management board position at Bayer, Dr Malik will have a broad perspective on how the industry should respond to the needs of different stakeholders.

Nicolas Sireau, Chairman, AKU Society

Described as "inspirational and innovative" Dr Nick Sireau will share his experiences in the identification and treatment of rare diseases, and how the pharma industry can adapt its business model to take advantage of the opportunities in this area

Jeremy Taylor, Chief Executive, National Voices

Jeremy is the voice of National Voices, which represents 15 million patients, and we’ll hear from him how the pharma industry can best serve the needs of the patient and carer com munity.

James Allen Heywood, Co-founder and Chairman, PatientsLikeMe

Jamie founded revolutionary healthcare initiative PatientsLikeMe which gives patients control and access to their healthcare information and compares it to others like them.  We'll hear from Jamie about how new healthcare models open up opportunities for the pharma industry,

Each year we hold an advisory board with key industry leaders in pharma to help us develop the programme and identify the critcal issues for discussion.

Attendees to this year's advisory board included:

Chair: Iain Scott, Senior Editor, Industry and Management Research, Economist Intelligence Unit

Virginia Acha, Associate Director, Policy Development, Pfizer

Jane Griffiths, Head of Market Access, Janssen-Cilag EMEA

Glen Hodgson,  Growth Director, Baxter Healthcare

Alex White, Vice-president, Europe, Emerging Markets, Asia-Pacific and Japan, GlaxoSmithKline

Frank Kumli, Lead Analyst Life Sciences, Ernst & Young

David Moran, Chief Executive Officer, Masters Pharmaceuticals

Richard Cassidy, Senior Director, Corporate Strategy and Planning, Astellas Pharma Europe

Stevo Knezevic, Head of Research and Development, Proximagen Group

Companies already confirmed to attend this year include:

Dealing with complex issues of fraud, regulatory compliance and business disputes can detract from efforts to achieve your company’s potential.  At Ernst & Young we have over 1,200 fraud investigation and dispute professionals to help you better manage your fraud risk and compliance exposure.  We assemble the right multidisciplinary and culturally aligned team to work with you and your legal advisors.  We give the benefit of our broad sector experience, deep subject matter knowledge and the latest insights from our work worldwide.

For further information visit www.ey.com

Freshfields is a leading international law firm, providing legal advice to clients throughout the world. With over 2,500 lawyers in 27 key business centres, the firm provides a comprehensive service to national and multinational corporations, financial institutions and government.

For further information visit www.freshfields.com

PharmaTimes Magazine was launched in 1988. The PharmaTimes portfolio includes the well-respected monthly industry Magazine; three news elert services including World, UK and Clinical news; business forums, where thought-leaders meet to discuss the issues of the day; and a unique series of awards that recognise, reward and celebrate excellence.

www.pharmatimes.com

Scripintelligence.com is the leading news, data and analysis service for the pharmaceutical and biotech industry. Scrip’s global coverage of business, R&D, policy & regulation, generics, drug development and clinical trials trends saves you valuable time and research costs.

Visit www.scripintelligence.com/freetrial today and register for free trial access.

Thomson Reuters can provide the knowledge, tools and expertise to help support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly-changing pharmaceutical and chemical markets, and make informed, early decisions.

science.thomsonreuters.com

M:Communications is Europe’s fastest growing and most sought after cross-border communications agency.   M:’s highly experienced international healthcare team has a deep knowledge, passion and understanding of the sector and a proven track record in offering a fully integrated service to cli­ents across all sub-sectors of healthcare.

www.mcomgroup.com

Please note:
* Your payment must be received prior to attendance.
** Discounts cannot be combined
*** Your registration fee includes refreshments, lunch and your conference materials.

1. ONLINE

Please note you will be directed to an external site to complete your booking.

2. BY POST OR FAX

Please download the registration form and return by:
FAX +44 (0)207 576 8472
POST Customer Services, Economist Conferences,
26 Red Lion Square, London, WC1R 4HQ, United Kingdom

3. BY PHONE

Please call customer services on +44 (0)207 576 8118